ESPR
Esperion Therapeutics, Inc.Healthcare · $661M market cap
Verdict
We can't put a fair value on ESPR right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ESPR
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds ESPR right now. In Q1 2026, 1 sold out. Who we track
Moves in Q1 2026
Sold out: Polen Capital Management
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Jul 13, 2026. How the Payback Price works